Tumor protein p53-induced nuclear protein (TP53INP1) expression in medullary thyroid carcinoma: A molecular guide to the optimal extent of surgery?

World Journal of Surgery

Volumn 34, Issue 4, 2010, Pages 830-835

  Taieb D ^a   Giusiano, S ^a,b   Sebag, F ^c   Marcy, M ^b   De Micco, C ^b   Palazzo, F F ^c   Dusetti, N J ^a   Iovanna, J L ^a   Henry, J F ^c   Garcia, S ^a,b   Taranger Charpin, Colette ^a,b  

^a INSERM   (France)

^b HÔPITAL NORD   (France)

^c TIMONE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CARRIER PROTEIN; HEAT SHOCK PROTEIN; TP53INP1 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CHI SQUARE DISTRIBUTION; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; LYMPHADENECTOMY; MALE; MEDULLARY CARCINOMA; METABOLISM; MIDDLE AGED; NONPARAMETRIC TEST; PATHOLOGY; STATISTICAL MODEL; THYROID TUMOR; WESTERN BLOTTING;

ADULT; AGED; BLOTTING, WESTERN; CARCINOMA, MEDULLARY; CARRIER PROTEINS; CHI-SQUARE DISTRIBUTION; FEMALE; HEAT-SHOCK PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; LOGISTIC MODELS; LYMPH NODE EXCISION; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; STATISTICS, NONPARAMETRIC; THYROID NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 77952429659     PISSN: 03642313     EISSN: 14322323     Source Type: Journal    
DOI: 10.1007/s00268-010-0395-6     Document Type: Article

References (38)

1. Dralle H, Scheumann GF, Proye C et al (1995) The value of lymph node dissection in hereditary medullary thyroid carcinoma: a retrospective, European, multicentre study. J Intern Med 238:357-361
2. Machens A, Hinze R, Thomusch O et al (2002) Pattern of nodal metastasis for primary and reoperative thyroid cancer. World J Surg 26:22-28
3. Machens A, Hofmann C, Hauptmann S et al (2007) Locoregional recurrence and death from medullary thyroid carcinoma in a contemporaneous series: 5-year results. Eur J Endocrinol 157:85-93
4. Oskam IM, Hoebers F, Balm AJ et al (2008) Neck management in medullary thyroid carcinoma. Eur J Surg Oncol 34:71-76
5. Hundahl SA, Fleming ID, Fremgen AM et al (1998) A National Cancer Data Base report on 53, 856 cases of thyroid carcinoma treated in the U.S., 1985-1995 (see Comments). Cancer 83:2638-2648
6. Modigliani E, Cohen R, Campos JM et al (1998) Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: results in 899 patients. The GETC Study Group. Groupe d'etude des tumeurs a calcitonine. Clin Endocrinol (Oxf) 48:265-273
7. Raue F, Kotzerke J, Reinwein D et al (1993) Prognostic factors in medullary thyroid carcinoma: evaluation of 741 patients from the German Medullary Thyroid Carcinoma Register. Clin Invest 71:7-12
8. Machens A, Gimm O, Ukkat J et al (2000) Improved prediction of calcitonin normalization in medullary thyroid carcinoma patients by quantitative lymph node analysis. Cancer 88:1909-1915
9. Scollo C, Baudin E, Travagli JP et al (2003) Rationale for central and bilateral lymph node dissection in sporadic and hereditary. medullary thyroid cancer. J Clin Endocrinol Metab 88:2070-2075
10. Weber T, Schilling T, Frank-Raue K et al (2001) Impact of modified radical neck dissection on biochemical cure in medullary thyroid carcinomas. Surgery 130:1044-1049
11. Ellenhorn JD, Shah JP, Brennan MF (1993) Impact of therapeutic regional lymph node dissection for medullary carcinoma of the thyroid gland. Surgery 114:1078-1081 (discussion 1081-1072)
12. Fleming JB, Lee JE, Bouvet M et al (1999) Surgical strategy for the treatment of medullary thyroid carcinoma. Ann Surg 230: 697-707
13. Kallinowski F, Buhr HJ, Meybier H et al (1993) Medullary carcinoma of the thyroid-therapeutic strategy derived from fifteen years of experience. Surgery 114:491-496
14. Kebebew E, Kikuchi S, Duh QY et al (2000) Long-term results of reoperation and localizing studies in patients with persistent or recurrent medullary thyroid cancer. Arch Surg 135:895-901
15. Machens A, Holzhausen HJ, Dralle H (2006) Contralateral cervical and mediastinal lymph node metastasis in medullary thyroid cancer: systemic disease? Surgery 139:28-32
16. Moley JF, DeBenedetti MK (1999) Patterns of nodal metastases in palpable medullary thyroid carcinoma: recommendations for extent of node dissection. Ann Surg 229:880-887 (discussion 887-888)
17. Moley JF, Fialkowski EA (2007) Evidence-based approach to the management of sporadic medullary thyroid carcinoma. World J Surg 31:946-956
18. Kloos RT, Eng C, Evans DB et al (2009) Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid 19:565-612
19. Iacobone M, Niccoli-Sire P, Sebag F et al (2002) Can sporadic medullary thyroid carcinoma be biochemically predicted? Prospective analysis of 66 operated patients with elevated serum calcitonin levels. World J Surg 26:886-890
20. Niccoli-Sire P, Murat A, Rohmer V et al (2003) When should thyroidectomy be performed in familial medullary thyroid carcinoma gene carriers with non-cysteine RET mutations? Surgery 134:1029-1036 (discussion 1036-1027)
21. Tamagnini P, Iacobone M, Sebag F et al (2005) Lymph node involvement in macroscopic medullary thyroid carcinoma. Br J Surg 92:449-453
22. Koperek O, Scheuba C, Cherenko M et al (2008) Desmoplasia in medullary thyroid carcinoma: a reliable indicator of metastatic potential. Histopathology 52:623-630
23. Machens A, Holzhausen HJ, Lautenschlager C et al (2003) Enhancement of lymph node metastasis and distant metastasis of thyroid carcinoma Cancer 98:712-719
24. Scheuba C, Kaserer K, Kaczirek K et al (2006) Desmoplastic stromal reaction in medullary thyroid cancer-an intraoperative "marker" for lymph node metastases. World J Surg 30:853-859
25. Gironella M, Seux M, Xie MJ et al (2007) Tumor protein 53-induced nuclear protein 1 expression is repressed by miR-155, and its restoration inhibits pancreatic tumor development. Proc Natl Acad Sci USA 104:16170-16175
26. Tomasini R, Samir AA, Carrier A et al (2003) TP53INP1s and homeodomain-interacting protein kinase-2 (HIPK2) are partners in regulating p53 activity. J Biol Chem 278:37722-37729
27. Tomasini R, Samir AA, Pebusque MJ et al (2002) P53-dependent expression of the stress-induced protein (SIP). Eur J Cell Biol 81:294-301
28. Tomasini R, Seux M, Nowak J et al (2005) TP53INP1 is a novel p73 target gene that induces cell cycle arrest and cell death by modulating p73 transcriptional activity. Oncogene 24:8093-8104
29. Herfarth KK, Wick MR, Marshall HN et al (1997) Absence of TP53 alterations in pheochromocytomas and medullary thyroid carcinomas. Genes Chromosom Cancer 20:24-29
30. Chevrier L, Meunier AC, Cochaud S et al (2008) Vasoactive intestinal peptide decreases MYCN expression and synergizes with retinoic acid in a human MYCN-amplified neuroblastoma cell line. Int J Oncol 33:1081-1089
31. Gommeaux J, Cano C, Garcia S et al (2007) Colitis and colitis-associated cancer are exacerbated in mice deficient for tumor protein 53-induced nuclear protein 1. Mol Cell Biol 27:2215-2228
32. Jiang PH, Motoo Y, Garcia S et al (2006) Down-expression of tumor protein p53-induced nuclear protein 1 in human gastric cancer. World J Gastroenterol 12:691-696 (Pubitemid 43380749)
33. Jiang PH, Motoo Y, Sawabu N et al (2006) Effect of gemcitabine on the expression of apoptosis-related genes in human pancreatic cancer cells. World J Gastroenterol 12:1597-1602
34. Machens A, Hauptmann S, Dralle H (2008) Prediction of lateral lymph node metastases in medullary thyroid cancer. Br J Surg 95:586-591
35. Jiang PH, Motoo Y, Iovanna JL et al (2004) Tumor protein p53-induced nuclear protein 1 (TP53INP1) in spontaneous chronic pancreatitis in the WBN/Kob rat: drug effects on its expression in the pancreas. JOP 5:205-216
36. Ito Y, Motoo Y, Yoshida H et al (2006) Decreased expression of tumor protein p53-induced nuclear protein 1 (TP53INP1) in breast carcinoma. Anticancer Res 26:4391-4395 (Pubitemid 46031512)
37. Ito Y, Motoo Y, Yoshida H et al (2006) High level of tumour protein p53-induced nuclear protein 1 (TP53INP1) expression in anaplastic carcinoma of the thyroid. Pathology 38:545-547
38. Nikiforova MN, Tseng GC, Steward D et al (2008) MicroRNA expression profiling of thyroid tumors: biological significance and diagnostic utility. J Clin Endocrinol Metab 93:1600-1608